| INTRODUCTION
Functional recovery and quality of life are important new treatment targets for patients with bipolar disorder (BD). While sustained symptomatic remission is an achievable goal with current pharmacological and psychological treatments, patients often do not recover full functional capacity, including work and social life. Indeed, quality of life is not merely the inverse of affective symptoms but also involves patients' perceptions of their position in life in the context of their culture, values and personal aspirations.
1 Poor life quality in BD is therefore closely linked to patients' lower academic attainment and vocational function, [2] [3] [4] high unemployment rates, 5, 6 and problems with household and community functioning. 7 This has led to growing consensus that clinical remission-ie, feeling well-is not a sufficient treatment goal: Patients also need to do well and recover functionally to achieve good quality of life.
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Persistent cognitive impairments across memory, attention, processing speed and executive function during periods of remission are directly related to poor quality of life 9 and socio-occupational outcome in BD. [10] [11] [12] [13] In fact, meta-analytic evidence indicates that memory and executive function are among the strongest contributors to occupational outcome in BD, with greater impact than residual mood symptoms. 13, 14 According to meta-analytic evidence, cognitive impairment in the remitted phase of BD is on average of a moderate effect size.
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However, recent studies revealed substantial cognitive heterogeneity in remitted BD patients: 12-40% of patients present global cognitive impairments across several domains, 29-40% show selective deficits in attention and psychomotor speed, and 32-48% are relatively 'cognitively intact' in comparison with norms. [16] [17] [18] Importantly, patients with either global or selective cognitive impairments reported poorer quality of life, more perceived stress and lower vocational function than patients who were cognitively intact, despite comparable levels of residual mood symptoms. 18, 19 It is therefore imperative to identify patients with persistent cognitive impairment, to characterize the pattern of their impairments, and to implement strategies for remediating these deficits to improve the clinical management of BD. To this end, there is a need for consensus on whether and how to screen for and treat cognitive impairment in clinical practice.
The International Society for Bipolar Disorders (ISBD) convened an expert task force in September 2016 under the lead of Dr. Miskowiak with the aim of developing (i) a consensus-based guidance paper for the methodology and design of cognition trials in bipolar disorder for pharmacological and non-pharmacological interventions, (ii) a clinical recommendations paper for clinicians on how to address cognitive impairments in their patients, and (iii) an educational patient booklet with information about cognitive impairment and pragmatic strategies for compensating for these in daily life. A paper addressing goal (i) was recently published in Bipolar Disorders. 20 The present paper addresses goal (ii), developing consensus-based clinical recommendations by this ISBD task force that can be used by clinicians to guide their choices on whether, when and how to assess and address cognition in their patients.
| METHODS
The ISBD Targeting Cognition Task Force was initiated by Dr. 
| The process of the task force
The task force work on goal (ii) was initiated with a face-to-face meeting between task force members during the ISBD Congress in 
| Brief cognitive screening

| What are the most feasible cognition screening tools in bipolar disorder?
A cognitive screening tool should be brief, easy and cost-effective for clinicians given time constraints and resource restrictions that make referral to a neuropsychologist untenable in most cases. There was consensus among task force members that the optimal way would be to have a simple, freely available "online package" which clinicians could use for all clinically stable adult patients in partial or full remission. Such a tool should include a few neurocognitive tests combined with questions about cognitive difficulties in daily life and mood status.
Since there is currently no such validated online cognition screener for bipolar disorder, the task force agreed to explore the possibility of developing such a tool as a next goal. Until such a tool is available, the recommendations are to use available paper-and-pencil tools that are validated for detection of cognitive impairment in bipolar disor- 
| Cognitive complaints in bipolar disorder rating assessment
The COBRA is a subjective cognitive impairment rating scale for 
| Cut-offs for impairment
Importantly, cut-offs for impairment on the SCIP and the COBRA should only be used as "rough guides" and should always be considered in the context of patient demographics, mood state and external outcome, such as ability to work, drive, and live independently. For the SCIP, it may be advisable to use a somewhat more conservative cut-off (ie, lower SCIP total score) for cognitive impairment in older patients than the published norm material 24, 35 given the age-related cognitive decline, 39 which is potentially accelerated in mood disorders. These instruments may be particularly suitable in cases where dementia is suspected because of ceiling effects in better functioning and/ or younger patients. In addition, given the potential complexity of differentiating the cognitive deficits in late-life BD from those associated with various types of dementia, referral for full neuropsychological evaluation would be recommended in some of these cases.
While the current norm material in some studies is based on age-, gender-and IQ-matched healthy control groups, it is not age-corrected per se, which reflects a current limitation that may be overcome with further normative data collection. Ongoing research aims to determine the optimal SCIP and COBRA cut-offs for cognitive impairment across a range of age groups including older patients. Another issue with using the published SCIP norms is that cognitive impairment may be difficult to detect in patients with substantial above-normal premorbid function. Thus, if logistically feasible, clinicians may consider cognitive impairment with reference to patients' cognitive reserve as reflected by their educational level or general IQ. Since higher COBRA scores correlated with greater symptom severity, 24 a more conservative cutoff (ie, a higher COBRA score) for impairment may therefore be considered for patients with substantial subsyndromal symptoms. Finally, linking cognitive impairment to external outcomes is also important for guiding treatment steps when cognitive impairment is detected (see implications and treatment perspectives under points 3.3.3 and 3.4).
| Minimum tools
In situations where it is not possible for clinicians to use the full SCIP and COBRA, or where these instruments are not available in the local language, the recommendation for "minimal assessments" would be to talk with the patient about their cognitive abilities in daily life, asking them to give specific examples, and combine this interview with one or two SCIP subtests, such as the verbal fluency and coding tests (which can be easily administered in any language and require minimal time/training). In particular, the SCIP coding test has shown sensitivity to cognitive change in response to medication effects and aging, and is therefore the recommended "minimum tool" to track cognition over time. However, for screening purposes, cutting down the SCIP to one or two subtests would be at the expense of assessment validity, since the tool is already short (<15 minutes) and constitutes a minimum of what can be considered a valid cognition assessment.
| Limitations of cognitive screeners
While brief cognitive screening tools can be administered by qualified mental health professionals after minimal training, take little time to administer, and are thus feasible in the clinical management of BD, these tools also have important limitations. They do not measure real life functions and cannot replace a comprehensive neuropsychological evaluation, which would give more detailed insight into which specific cognitive deficits may be related to the patients' particular psychosocial difficulties. 44 The SCIP is therefore not a substitute for a comprehensive neuropsychological examination, but is merely a useful initial tool to screen patients who may benefit from a more thorough assessment to rule out cerebral pathology. For example, in cases where rapid declines in cognitive function occur (and/or are accompanied by other symptoms such as confusion or headache) or when function is highly discordant with current mood state/function, brief screening would not be adequate. Brief cognitive screening therefore cannot replace such full diagnostic evaluations, and if they show some clear deficits, this may also trigger a referral for a more comprehensive specialist assessment.
| What are the implications if cognitive impairment is detected on a brief tool?
It may be argued that clinicians should not screen for something if It is important to consider and address these common causes of secondary or pseudo-specific cognitive deficits before a "true" illness-associated cognitive impairment can be assumed. In many cases, addressing such secondary causes of cognitive deficits will result in significant cognitive improvement.
| Referral to a thorough neuropsychological evaluation
| Patient recommendations
Detection of persistent cognitive impairments can provide a basis for recommendation of compensational strategies, adjustment of work responsibilities or rehabilitative interventions to improve functioning.
Specifically, the assessments can be used to inform patients and their relatives about the nature and consequences of cognitive impairment which may help patients tackle and compensate for these difficulties in daily life. By increasing patients' and their families' insights into the nature and impact of residual cognitive impairments, the assessments may encourage patients to implement compensation strategies and reduce potential interpersonal problems (for example, family members' irritation or disappointment when patients forget daily chores or anniversaries). When patients wish to resume work, brief assessment of their cognitive status can become an important basis for adjustment of work demands and reduce expectations so they are realistic.
Finally, cognitive screening assessment can also provide impetus for good habits including getting regular and sufficient sleep and physical exercise, restricting alcohol intake, and adhering to treatment.
Another important way of reducing cognitive impairment in BD is implementation of strategies to boost patients' cognitive reserve, the capacity of the brain to tolerate neuropathology, reduce symptom manifestations and manage cognitive challenges. 47 Specifically, high cognitive reserve-which is estimated by patients' premorbid IQ, educational level • Obtain the SCIP and COBRA-which exist in multiple languages and are freely available-through the ISBD website at (www.isbd. org/cognitive-assessment) (III) What are the implications if cognitive impairment is detected?
• Evaluate the potential impact of medication, comorbidity and symptoms when impairment is detected to discriminate between "secondary" and "primary" causes of cognitive impairments-and adjust medication if necessary to reduce cognitive side effects
• Consider referral for more comprehensive neuropsychological evaluation when there is a substantial impairment in the screening, when there is concern about organic brain illness, comorbidity, or cognitive decline, when there is a need to evaluate multiple cognitive domains in greater detail, when there is a question of poor effort affecting validity of test results, or when premorbid/developmental/ learning problems may be complicating the cognitive picture
• Inform patients and relatives about the nature and possible consequences of patients' cognitive impairments and encourage compensation strategies, support and adjustment of expectations
• Encourage patients to implement good habits, including regular sleep and exercise, and to build up their cognitive reserve by engaging in education and vocational activities (IV) What are the treatment perspectives?
• There is currently no clinically available treatment with efficacy on cognition but intense research effort is likely to reveal effective treatments within the next few years
• Promising pharmacological candidate treatments are: mifepristone, lurasidone, erythropoietin (EPO), vortioxetine and modafinil
• Promising psychological interventions are functional remediation and cognitive remediation programs including action-based cognitive remediation and occupational attainment 48 -is thought to slow down the clinical presentation of neurocognitive decline, whereas low cognitive reserve may exacerbate cognitive decline. 47, 49 Cognitive screening assessments can motivate patients to build up their cognitive reserve to prevent further cognitive decline and even improve their cognitive outcome.
| What are the treatment perspectives?
There are no available treatments with documented direct procognitive effects in BD, despite the pressing need for such treatments to enhance functional recovery and reduce societal costs. 20 The unmet clinical need is partially due to several major methodological challenges in cognition trials in BD, which have been addressed and discussed by the task force in a recently published methodological guidance paper.
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However, current research effort is likely to reveal effective pharmacological and psychological treatments within the next few years.
| Promising pharmacological treatments
Among the most promising candidate pharmacological treatments are the corticosteroid receptor antagonist mifepristone, the atypical antipsychotic lurasidone, the multifunctional neurotrophic growth factor erythropoietin (EPO), the antidepressant vortioxetine and nonamphetamine stimulant modafinil. In particular, two studies of mifepristone (a 1-week cross-over study and a 3-week parallel study) in moderately depressed patients with BD found beneficial effects on spatial working memory (but not on other cognitive domains). 
F I G U R E 1 Recommendations for clinical assessment of cognition in bipolar disorder
Is the patient in partial or full remission?
• Modafinil-which was originally intended to treat narcolepsy-is a promising candidate treatment based on findings from a recent RCT in remitted patients with unipolar disorder. Specifically, beneficial effects of a single dose (200 mg) of modafinil over placebo were observed on episodic memory and working memory (but not on executive function or sustained attention) in these remitted patients. 56 Further, the antidepressant vortioxetine was found in several RCTs to improve some aspects of cognition in unipolar disorder, which seemed to be partially independent of its antidepressant actions and was also recently shown in remitted patients. 57, 58 Studies are therefore warranted to investigate the ability of these compounds to improve cognitive function in BD.
| Promising psychological treatments
Promising psychological treatments for cognitive and functional impairments in BD are functional remediation (FR) and certain cognitive remediation (CR) programs including action-based cognitive remediation (ABCR). FR and ABCR both involve cognitive training, compensation techniques and coping strategies to overcome cognitive difficulties in daily life situations. However, while FR focuses primarily on the training of neurocognitive strategies and psychosocial skills,
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ABCR emphasizes computerized cognitive training and transfer of the learned skills to daily life challenges by practical in-session exercises and actively seeking cognitive challenges in daily life. Functional remediation seems a viable option for patients presenting cognitive and psychosocial impairments because it has been shown to be effective at improving functioning in patients in late states of illness. 59, 60 While a large RCT did not show significant benefits of 21 weeks of FR on cognition, this may be because of the study design which involved enrichment for functional impairment but not for cognitive deficits.
Indeed, exclusion of the patients who were cognitively intact revealed a significant treatment benefit in verbal memory function. 61 In addition, several naturalistic or quasi-experimental studies of different CR programs for BD have been conducted over the past decade with encouraging preliminary results. [62] [63] [64] [65] [66] The first published RCT of 12 weeks of group-based CR showed no efficacy on objective cognition. 67 However, a newly published study revealed positive effects of 70-hour computerized CR. 46 Notably, a non-randomized controlled trial of 10 weeks of ABCR was recently found to improve not only cognition but also vocational function in a mixed group of patients with severe mental illnesses (schizophrenia, unipolar disorder and BD). 68 Based on this evidence, two parallel RCTs were recently set up to investigate the effects of 10 weeks of ABCR in cognitively impaired patients with BD in remission and their first-degree relatives. 69 Other ongoing RCTs are investigating the effects of 12 weeks of cognitivebehavioral rehabilitation, 70 12 weeks of cognitive remediation 71 and 24 weeks of internet-based cognitive remediation for BD I.
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A highly promising treatment approach is the combination of pharmacological and psychological interventions (eg,
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). This is likely to produce synergistic effects on brain function that may translate into more robust efficacy on cognition and functional outcome than either treatment modality alone. Multimodal treatment approaches are therefore considered a key next step for cognition trials in BD that is likely to reveal new effective treatment options.
| CONCLUSIONS
Cognition is a new key treatment target in BD but there has been a lack of consensus on how cognitive impairment should be assessed and managed. This ISBD Targeting 
